Xp11 translocation cancers include Xp11 translocation renal cell carcinoma (RCC), Xp11 translocation perivascular epithelioid cell tumor (PEComa), and melanotic Xp11 translocation renal cancer. In Xp11 translocation cancers, oncogenic activation of TFE3 is driven by the fusion of TFE3 with a number of different gene partners; however, the impact of individual fusion variant on specific clinicopathologic features of Xp11 translocation cancers has not been well defined. In this study, we analyze 60 Xp11 translocation cancers by fluorescence in situ hybridization using custom bacterial artificial chromosome probes to establish their TFE3 fusion gene partner. In 5 cases RNA sequencing was also used to further characterize the fusion transcripts. The 60 Xp11 translocation cancers included 47 Xp11 translocation RCC, 8 Xp11 translocation PEComas, and 5 melanotic Xp11 translocation renal cancers. A fusion partner was identified in 53/60 (88%) cases, including 18 SFPQ (PSF), 16 PRCC, 12 ASPSCR1 (ASPL), 6 NONO, and 1 DVL2. We provide the first morphologic description of the NONO-TFE3 RCC, which frequently demonstrates subnuclear vacuoles leading to distinctive suprabasal nuclear palisading. Similar subnuclear vacuolization was also characteristic of SFPQ-TFE3 RCC, creating overlapping features with clear cell papillary RCC. We also describe the first RCC with a DVL2-TFE3 gene fusion, in addition to an extrarenal pigmented PEComa with a NONO-TFE3 gene fusion. Furthermore, among neoplasms with the SFPQ-TFE3, NONO-TFE3, DVL2-TFE3, and ASPL-TFE3 gene fusions, the RCCs are almost always PAX8 positive, cathepsin K negative by immunohistochemistry, whereas the mesenchymal counterparts (Xp11 translocation PEComas, melanotic Xp11 translocation renal cancers, and alveolar soft part sarcoma) are PAX8 negative, cathepsin K positive. These findings support the concept that despite an identical gene fusion, the RCCs are distinct from the corresponding mesenchymal neoplasms, perhaps due to the cellular context in which the translocation occurs. We corroborate prior data showing that the PRCC-TFE3 RCCs are the only known Xp11 translocation RCC molecular subtype that are consistently cathepsin K positive. In summary, our data expand further the clinicopathologic features of cancers with specific TFE3 gene fusions and should allow for more meaningful clinicopathologic associations to be drawn.
X p11 translocation renal cell carcinomas (RCC) were first officially recognized by the World Health Organization in 2004, following the initial detailed morphologic descriptions that were published in 2001 and 2002. 1, 2 Xp11 translocation RCC bear chromosome translocations that result in 1 of a variety of gene fusions that involve the TFE3 transcription factor gene, which maps to the Xp11.2 locus. Reported TFE3 fusion partners include ASPSCR1 (ASPL), PRCC, SFPQ1 (PSF), NONO, CLTC, PARP14, LUC7L3, and KHSRP. [3] [4] [5] [6] Xp11 translocation RCCs comprise the majority of pediatric RCC and approximately 1% to 4% adult RCCs. [7] [8] [9] [10] Although a variety of morphologic patterns have been described, 11 the most common appearance is that of an RCC with papillary architecture, clear cells, and psammoma bodies. By immunohistochemistry, these tumors frequently underexpress cytokeratins, but frequently express melanocytic markers and the cysteine protease cathepsin k, which distinguishes them from more common RCC subtypes. [12] [13] [14] Overall, outcome is similar to that of clear cell RCC, with increased age and advanced stage being poor prognostic factors. 15, 16 Although immunohistochemistry for overexpressed TFE3 fusion proteins was initially the only method to confirm this diagnosis in formalin-fixed, paraffin-embedded archival material, 17 break-apart fluorescence in situ hybridization (FISH) demonstrating TFE3 gene rearrangement is now the preferred method. 10, 11, 18, 19 However, TFE3 breakapart FISH does not provide information as to the specific fusion partners of TFE3. In fact, data on the clinicopathologic features of the subtypes of Xp11 translocation RCC associated with specific fusion partners are limited, as demonstration of the fusion partner has typically required fresh tissue for either cytogenetics or reverse transcriptase polymerase chain reaction assays.
Two other Xp11 translocation cancers that morphologically overlap with the Xp11 translocation RCC include Xp11 translocation perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers. Xp11 translocation PEComas differ from typical PEComas in that they typically affect younger patients, have purely or predominantly epithelioid clear cell morphology, are not associated with tuberous sclerosis syndrome, do not express muscle markers by immunohistochemistry, and are not associated with TSC2 gene alterations. [20] [21] [22] [23] [24] The most commonly identified fusion in Xp11 translocation PEComas has been SFPQ-TFE3, with a rare case demonstrating a DVL2-TFE3 gene fusion. 22 Melanotic Xp11 translocation renal cancers were initially described before the Xp11 PEComas and have been thought to overlap most with PEComa, although their renal origin raised the possibility of their representing Xp11 translocation RCCs that do not express renal tubular markers. [24] [25] [26] Significant morphologic overlap between Xp11 translocation RCC, Xp11 translocation PEComa, and melanotic Xp11 translocation renal cancers has been described. In the few cases of melanotic Xp11 translocation renal cancer in which a specific fusion has been identified, the gene fusion has always been SFPQ-TFE3. 24, 26 The development of FISH probes for the commonly identified TFE3 fusion partners allows subtyping of Xp11 translocation neoplasms in archival material, vastly increasing the number of cases that can be analyzed. Subtyping of Xp11 translocation-associated cancers should allow more meaningful clinicopathologic associations to be drawn, such as the differences previously described in a review of the published literature between the ASPSCR1-TFE3 RCC and the PRCC-TFE3 RCC. 16 In this study, we apply a large battery of these fusion-partner probes to a cohort of confirmed TFE3-rearranged Xp11 translocation cancers by break-apart FISH and correlate the subtype with clinicopathologic features. We also corroborate the results in 5 cases using RNA sequencing (RNAseq).
MATERIALS AND METHODS

Case Selection and FISH Analysis
The cases studied included 60 cases collected from the consultation files of 3 of the authors (P.A., V.E.R., C.R.A.) and additional cases collected from the institutional files of The Johns Hopkins Medical Institutions and Memorial Sloan Kettering Cancer Center. Twenty of these cases were previously reported but without data as to fusion partner subtype in a prior study demonstrating the efficacy of TFE3 break-apart FISH in renal tumor consultations. 11 Two other cases of Xp11 translocation PEComa in this study were included from the original description of this entity, 20 and 1 other case was reviewed by one author (P.A.) in consultation and subsequently reported by others. 27 One case of melanotic Xp11 translocation renal cancer in this study was included in the original description of this entity, 25 and 2 other cases were reviewed by one author (P.A.) in consultation and subsequently reported by others. 28, 29 Immunohistochemistry for PAX8 (which is almost always negative in PEComa) 30 and cathepsin K (which is consistently positive in PE-Coma) was performed as previously described. 12 For RCC, staging was performed using the American Joint Commission on Cancer Manual, seventh edition. 31 This study was approved by the Institutional Review Boards at participating Institutions.
FISH on interphase nuclei from paraffin-embedded 4-mm-thick sections was performed applying custom probes using bacterial artificial chromosomes (BAC), covering and flanking genes of interest. TFE3 break-apart FISH was performed as previously described. 11 BAC clones were chosen according to UCSC genome browser (http://genome.ucsc.edu) (see Supplementary Table 1 , Supplemental Digital Content 1, http://links.lww.com/ PAS/A351). The BAC clones were obtained from BAC-PAC sources of Children's Hospital of Oakland Research Institute (CHORI) (Oakland, CA) (http://bacpac.chori.org). DNA from individual BACs was isolated according to the manufacturer's instructions, labeled with different fluorochromes in a nick translation reaction, denatured, and hybridized to pretreated slides. Slides were then incubated, washed, and mounted with DAPI in an antifade solution, as previously described. 32 The genomic location of each BAC set was verified by hybridizing them to normal metaphase chromosomes. Two hundred successive nuclei were examined using a Zeiss fluorescence microscope (Zeiss Axioplan, Oberkochen, Germany), controlled by Isis 5 software (Metasystems, Newton, MA). A positive score was interpreted when at least 20% of the nuclei showed a break-apart signal. Nuclei with incomplete set of signals were omitted from the score.
RNA-seq and Data Analysis
To verify FISH results in 5 selected cases with available material, RNA-seq was performed as described previously. 5 Briefly, total RNA was extracted after xylene deparaffinization, using the AllPrep DNA/ RNA FFPE Kit (Qiagen, Hilden, Germany). The quantity and integrity of the RNA was measured using the Agilent 2100 Bioanalyzer. One hundred nanograms of the RNA was applied for sequencing library preparation using the TruSeq RNA Access Library Prep Kit (Illumina, San Diego) as per the manufacturer's protocol. Paired-end sequencing (75 bp Â 2) was performed using the MiSeq Reagent V3 Kit (150 cycles) and the MiSeq sequencing system (Illumina). STAR algorithm was used for detection of any potential TFE3 fusion. Bowtie2 was used for alignment and mapping of short sequence reads to the human genome reference hg19 and the fusion transcript SFPQ/PSF-TFE3. Integrative Genomics Viewer was used for data visualization (Fig. 1 
RESULTS
A total of 60 cases with known TFE3 gene rearrangements demonstrated by TFE3 break-apart FISH were analyzed for fusion partners. These included 47 Xp11 translocation RCCs, 8 Xp11 translocation PEComas (2 renal, 6 nonrenal), and 5 melanotic Xp11 translocation renal cancers. A fusion partner was identified in 53 cases (88%), including 18 SFPQ (PSF), 16 PRCC, 12 ASPSCR1 (ASPL), 6 NONO, and 1 DVL2 ( Fig. 1 ). In the remaining 7 (12%) cases no gene partner was identified using the available probes, including custom BACs for the above genes and for additional less common TFE3 gene partners reported, such as CLTC, YAP1 (re-cently shown to be fused to TFE3 in a subset of epithelioid hemangioendotheliomas), 33 or PARP14. The results for specific subtypes are presented according to the specific gene rearrangement identified. 
NONO-TFE3 RCC (5 Cases)
These 5 cases affected 3 male and two female individuals (mean age 38.4 y, median 36 y) ( Table 1 , cases 1 to 5). Two cases presented as small localized RCCs, 1 each presented with regional lymph node and bone metastases, whereas another presented as localized stage 1 disease but developed lung metastases after 2 years. Morphologically, the tumors showed a combination of nested to papillary architecture and predominantly clear cytoplasm. Four of 5 cases demonstrated psammomatous calcifications. Four of the 5 cases demonstrated nuclear palisading with subnuclear vacuoles, a pattern that mimics clear cell papillary RCC 34, 35 (Figs. 2, 3 ). This pattern was focal (present in <50% of the tumor) in 2 cases and diffuse (present in >50% of the tumor) in the other 2. In the fifth case, nuclear palisading resembled a trabecular architecture, leading to an initial impression of a neuroendocrine neoplasm. By immunohistochemistry, all 5 cases were immunoreactive for PAX8, but none expressed cathepsin K (PAX8+, cathepsin K À). All 5 cases were negative for carbonic anhydrase IX (CA-IX). Two of 5 cases had rare cytokeratin 7-positive cells with the other 3 cases being completely negative.
NONO-TFE3 PEComa With Melanin Pigment (1 Case)
This neoplasm presented as an orbital mass in a 20year-old man ( Table 1 , case 6). The morphology was that of a nested epithelioid neoplasm, with clear to finely granular eosinophilic cytoplasm, typical of an Xp11 translocation PEComa, with the exception of abundant melanin pigment ( Fig. 4 ). By immunohistochemistry, this neoplasm had the opposite immunoreactivity of the NONO-TFE3 RCC; being positive for cathepsin K, but not for PAX8 (PAX8À , cathepsin K+). Clinical followup information on this case is not available.
DVL2-TFE3 RCC (1 Case)
This neoplasm was a 14.5 cm renal tumor in a 73year-old man. The tumor demonstrated papillary and solid architecture with focal sarcomatoid areas, had variably eosinophilic cytoplasm, and presented with right perirenal lymph node metastases (pT3N1). By immunohistochemistry, the neoplasm was positive for PAX8, but negative for cathepsin K and melan A ( Fig. 5 ). For comparison, we performed PAX8 and cathepsin K immunohistochemistry on a previously reported DVL2-TFE3 PEComa, a 5.5 cm tumor located on the calf. 22 The PEComa demonstrated the opposite pattern as the RCC with the same DVL2-TFE3 gene fusion; it was PAX8 negative and cathepsin K positive (not shown).
SFPQ-TFE3 RCCs (7 Cases)
Seven RCCs harbored an SFPQ-TFE3 gene fusion. These cases occurred in patients ranging from 19 to 63 years of age (mean 39, median 36), and 6 of 7 occurred in female individuals ( Table 2 , cases 1 to 7). All cases were initially confined to the kidney. Case 1 presented as pT2 disease, had sarcomatoid morphology, and later recurred in the retroperitoneum. Morphologically, the tumors showed a combination of nested to papillary architecture and predominantly clear cytoplasm. All 7 cases demonstrated psammomatous calcifications. Five of these 7 cases demonstrated striking subnuclear vacuoles, similar to those seen in clear cell papillary RCC and (as shown above) in the RCC with NONO-TFE3 gene fusion. In all 5 cases, this pattern was diffuse (present in >50% of the tumor). In areas in which the subnuclear vacuoles were less evident, the morphology was typically that of a nested epithelioid clear cell neoplasm with thin capillary vasculature, closely mimicking clear cell RCC (Figs. 6, 7). Six of these 7 RCCs were reactive for PAX8 but not for cathepsin K (PAX8+, cathepsin k À). The other case (case 6) was positive for PAX8 and focally positive for cathepsin K in cystic areas of the tumor. All 3 tested cases were negative for cytokeratin 7. Three of 4 cases were completely negative for CA-IX, whereas 1 case demonstrated rare positive cells.
SFPQ-TFE3 PEComas (7 Cases)
These neoplasms comprised 7 of the 8 Xp11 translocation PEComas available for study (the other case demonstrated a NONO-TFE3 gene fusion described above). Six patients were female, and 1 was male. Patient (Table 1 , case 6). A and B, This is a neoplasm with nested to alveolar architecture, which features epithelioid cells with clear to finely granular eosinophilic cytoplasm. Fine pigment that proves to be melanin is present in the cytoplasm. The neoplasm was immunoreactive for melan A (not shown). The neoplasm does not label for PAX8 (C) but shows diffuse immunoreactivity for cathepsin K (D).
predominantly clear to focally eosinophilic cytoplasm. All cases analyzed were diffusely immunoreactive for cathepsin K, but negative for PAX8 (PAX8 À , cathepsin k+) ( Fig. 8 ). All cases were immunoreactive for HMB45, but only 4 of 6 were immunoreactive for melan A. None of these cases demonstrated melanin pigment.
Both cases with adequate RNA for RNA seq demonstrated an SFPQ-TFE3 gene fusion, fusing exon 9 of SFPQ with exon 6 of TFE3 ( 
SFPQ-TFE3 Melanotic Xp11 Translocation Renal Cancers (4 Cases)
These comprised 4 of the 5 tested cases (the other case did not have an identifiable fusion partner). The patients ranged in age from 11 to 34 years (mean 27, median 24) ( Table 2 , cases 15 to 18). Two patients presented with disseminated metastatic disease. All of these cases demonstrated a solid nested architecture featuring epithelioid cells with predominantly clear to focally eosinophilic cytoplasm, along with melanin pigment readily identifiable on hematoxylin and eosin sections. All of these neoplasms labeled diffusely for cathepsin K, and all were negative for PAX8 (PAX8À , cathepsin k+). All 3 cases with adequate RNA for RNA-seq demonstrated an SFPQ-TFE3 gene fusion, fusing exon 9 of SFPQ with exon 6 of TFE3 ( 
ASPSCR1-TFE3 RCC (12 Cases)
These patients ranged in age from 15 to 73 years (mean 33.75, median 27), and 9 were female and 3 were male individuals (Table 3) . Morphologically, all neoplasms demonstrated the typical morphology of this subtype, specifically, nested to papillary architecture, voluminous clear to eosinophilic cytoplasm, and abundant psammoma bodies. Two of 3 cases with lymph nodes examined harbored lymph node metastases at diagnosis, and all 9 cases tested were negative for cathepsin K.
PRCC-TFE3 RCC (16 Cases)
These patients ranged in age from 5 to 63 years (mean 40.3, median 42), with an equal sex distribution, 8 female and 7 male individuals, and 1 of unknown sex (Table 4) . Morphologically, all tumors demonstrated the typical morphology of this subtype; specifically, they demonstrated compact nested to papillary architecture, clear to eosinophilic cytoplasm, and psammoma bodies. One case demonstrated palisading of nuclei and another demonstrated subnuclear vacuoles similar to RCC harboring SFPQ-TFE3 and NONO-TFE3 fusions, as described above. Seven of the 11 tested cases were immunoreactive for cathepsin K. Of note, 2 patients presented with hematogenous metastasis, which has not previously been reported in this subtype of Xp11 translocation RCC. 
TFE3-rearranged Neoplasms With Unknown Fusion Partner (7 Cases)
The clinicopathologic features of these cases are summarized in Table 5 . These included 6 Xp11 translocation RCCs and 1 melanotic Xp11 translocation cancer. Of note, all of the RCCs were cathepsin K positive. Two of the RCCs were extensively cystic, and 2 had biphasic morphology mimicking t(6;11) RCC as previously described. 11 Adequate material for RNA-seq was available from the melanotic Xp11 translocation cancer; however, a TFE3 fusion partner could not be identified
DISCUSSION
In this study, we apply combined molecular methodologies, FISH and RNA seq, to establish a detailed characterization of TFE3 fusion partners in a large cohort of Xp11 translocation-positive neoplasms. First, we provide the first morphologic description of the NONO-TFE3 RCC. Previously, a single case of this entity had been reported, 3 but a morphologic description and images were not provided. We found that this neoplasm and the SFPQ-TFE3 RCC (see below) frequently demonstrate subnuclear vacuoles, leading to palisading of nuclei, similar to the appearance of clear cell papillary RCC. All 5 cases were immunoreactive for PAX8, but negative for cathepsin K. This immunoprofile contrasts with that of the Xp11 translocation PEComa harboring identical NONO-TFE3 gene fusion (a fusion not previously reported in Xp11 translocation PEComa until now), which was conversely immunoreactive for cathepsin K but not for PAX8. We note that the presence of NONO-TFE3 gene fusion can be suspected on the basis of the pattern of TFE3 rearrangement by FISH, showing constant, small gaps between the telomeric and centromeric TFE3 signals, in keeping with an inversion/intrachromosomal fusion.
We also report the first RCC with a DVL2-TFE3 gene fusion. This tumor had a variety of morphologic patterns, including oncocytic, tubular, and sarcomatoid features. DVL2-TFE3 fusion has been previously reported in an Xp11 translocation PEComa. 22 In our study, similar to the NONO-TFE3 neoplasms, we found that the DVL2-TFE3 RCC was PAX8 positive and cathepsin K negative, whereas the DVL2-TFE3 PEComa was cathepsin K positive and PAX8 negative.
We identified 18 neoplasms in this study harboring SFPQ-TFE3 gene fusions. Prior studies have suggested significant overlap among Xp11 translocation RCC, Xp11 translocation PEComa, and melanotic Xp11 translocation renal cancers bearing the SFPQ-TFE3 gene fusion. Some have grouped all neoplasms with the SFPQ-TFE3 gene fusion together 36 and suggested that the distinction may be arbitrary. We have seen cases in which the same renal tumor has been seen by experts at several different major academic centers and been classified as RCC by some and PEComa by others. Along these lines, we originally classified 1 of the cases in this study as an RCC on the basis of its nested epithelioid morphology and renal location but, on rereview of the morphology and immunohistochemical profile, reclassified it as a PEComa (Table 2, case 8). A complete immunohistochemical profile of tumors classified as RCC with the SFPQ-TFE3 gene fusion has not been reported. We show herein that RCCs with the SFPQ-TFE3 gene fusion are immunoreactive for PAX8 and almost always negative for cathepsin K, which distinguishes them from Xp11 translocation PEComa and melanotic Xp11 translocation renal cancer and frequently have a distinctive morphology featuring subnuclear vacuoles and nuclear palisading, similar to that seen in the NONO-TFE3 RCC. The similar morphology of the SPFQ-TFE3 and NONO-TFE3 RCC is intriguing given the highly overlapping functions of SFPQ and NONO in RNA processing, and the fact that they together form protein complexes. 37 We note that, in retrospect, subnuclear vacuoles are readily seen in the published images provided in 4 case reports of SFPQ-TFE3 RCC, although not commented on in these publications. [38] [39] [40] [41] The frequent subnuclear vacuolization seen indicates that these Xp11 translocation RCCs should also be considered in the differential diagnosis of clear cell papillary RCC. Unlike clear cell papillary RCCs, SFPQ-TFE3 and NONO-TFE3 RCCs frequently occur in younger patients, frequently have psammomatous calcifications, and show no or minimal immunoreactivity for cytokeratin 7 and CA-IX. We also found that the SFPQ-TFE3 RCC frequently mimics clear cell RCC to a striking degree. In fact, 2 of the cases in our study were previously diagnosed as clear cell RCC by experienced surgical pathologists with extensive expertise in urologic pathology consultations before they were reviewed in the course of this study. This morphologic mimicry of clear cell RCC also explains the observation that all 5 Xp11 translocation RCCs mistakenly included in the cancer genome atlas (TCGA) sequencing study of clear cell RCC contained the SFPQ-TFE3 RCC fusion. 42 On the basis of these findings, we believe that the SFPQ-TFE3 RCCs are the Xp11 translocation RCC most likely to mimic clear cell RCC. The frequently younger patient age, focal papillary architecture, psammomatous calcification, and absence of or minimal labeling for CA-IX are clues to the diagnosis of SFPQ-TFE3 RCC.
The usual PAX8-positive cathepsin K-negative immunoprofile of the SFPQ-TFE3 RCC contrasts with those of the Xp11 translocation PEComa and melanotic Xp11 translocation RCC that harbor the same gene fusion, both of which were consistently cathepsin K positive and PAX8 negative. These findings suggest that the SFPQ-TFE3 RCCs are a distinctive entity that can be separated in the majority of cases from Xp11 translocation PEComa and melanotic Xp11 translocation cancers. The latter 2 neoplasms share a similar immunoprofile (PAX8 negative, cathepsin K positive), which supports our original view and subsequently that of others that melanotic Xp11 translocation renal cancers likely represent a variant of or part of the spectrum of Xp11 translocation PEComa. Further evidence of overlap is the presence of melanin in several extrarenal Xp11 translocation neoplasms, including the NONO-TFE3 PEComa in this study, an SFPQ-TFE3 PEComa of the pancreas, pelvis, and cervix reported by Rao et al, 24 along with an ovarian melanotic Xp11 translocation neoplasm previously reported in the literature. 43 Although the phenotype of the Xp11 translocation RCC and Xp11 translocation PEComas is distinct at the immunohistochemical level, it is clear that these lesions are genetically related and can be considered part of a family of cancers driven by TFE3 gene fusions. This suggests the potential for utilization of novel targeted therapies that are effective against one member against the others.
Our data on RCC with the ASPCR1-TFE3 and PRCC-TFE3 RCC add supporting data to the published findings. We had previously shown that cathepsin K is frequently positive in the PRCC-TFE3 RCC but consistently negative in the ASPCR1-TFE3 RCC, a finding that is confirmed in this study. 14 Two of 3 ASPSCR1-TFE3 RCCs in which lymph nodes were resected were associated with lymph node metastasis, which corroborates tendency to lymph node involvement we previously described in this subtype. 16 Furthermore, 2 patients with small, seemingly localized ASPCR1-TFE3 RCC who did not initially undergo node sampling at presentation (pT1NX) later recurred with involvement of retroperitoneal lymph nodes, suggesting the possibility that nodal sampling at diagnosis could have impacted outcome. A previous review of the literature showed that PRCC-TFE3 RCC typically present at lower stage than do the ASPCR1-TFE3 RCC, 16 but in this study we report the first 2 cases of PRCC-TFE3 RCC that presented with metastatic disease. We note that neither of the ASPCR1-TFE3 and PRCC-TFE3 gene fusions was or has previously been identified in an Xp11 translocation PEComa. The ASPCR1-TFE3 gene fusion is of course characteristic of the mesenchymal neoplasm alveolar soft part sarcoma, 44 but there is no currently identified mes- (Table 6 ). It should be noted, however, that all of the Xp11 RCCs in this study that do not as of now demonstrate a known fusion partner were positive for cathepsin K, suggesting that the as yet unknown TFE3 fusion partners involved in these cases may function similarly to PRCC. Given the variable clinical presentation and morphologic appearances described in this and other manuscripts, one could be tempted to conclude that all RCCs be worked up by molecular techniques to exclude Xp11 translocation RCC. As the prognosis for Xp11 translocation RCC is similar to that of clear cell RCC, a missed diagnosis of a localized Xp11 translocation RCC as clear cell papillary RCC would result in the patient receiving an inappropriately optimistic report of their prognosis. For cases that present with metastatic disease, the diagnosis of Xp11 translocation RCC would make a patient ineligible for some treatments designed to specifically target clear cell RCC and eligible for treatments that target cancers with TFE3 gene fusions. However, we believe that comprehensive molecular analysis of all RCCs is not cost-effective. Our view is that RCCs with classic clinical presentation and morphology that is typical of the specific common subtypes of RCC (such as clear RCC, papillary RCC, and chromophobe RCC) do not require immunohistochemical stains or molecular analysis for diagnosis: the diagnosis can be comfortably reached on routine H&E sections. For other cases in which the morphology or clinical presentation is slightly unusual, we typically perform a limited immunohistochemical profile (such as cytokeratin 7, CA-IX, and cathepsin K) to support or refute the suspected diagnosis. If this does not clarify the diagnosis, further workup is indicated. We do not routinely perform TFE3 FISH unless there is a strong clinical suspicion (age less than 30 y), highly suggestive morphology (such as papillary architecture with clear cells and psammoma bodies), or highly suggestive immunohistochemical results (such as diffuse cathepsin K immunoreactivity). We also perform TFE3 FISH for many unclassified RCCs, given the morphologic variability demonstrated by Xp11 translocation RCC including its ability to have a nondescript high-grade RCC appearance.
In summary, our study highlights the ability of a subset of Xp11 translocation RCCs to mimic clear cell papillary RCC and clear cell RCC. Clinical clues such as young age, morphologic clues such as the presence of psammoma bodies, and immunohistochemical clues such as minimal immunoreactivity for CA-IX should suggest the possibility of Xp11 translocation RCC. Our study also highlights the different immunohistochemical phenotypes of Xp11 translocation RCCs and PEComas that harbor the same gene fusion. Despite morphologic overlap, PAX8 and cathepsin K can distinguish most cases. We also highlight the strong association of cathepsin K immunoreactivity in Xp11 translocation RCC with the presence of a PRCC-TFE3 gene fusion.
